Published in Int J Radiat Oncol Biol Phys on April 18, 2008
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol (2010) 2.17
Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol (2009) 1.76
Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys (2012) 1.43
Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med (2012) 1.34
Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist (2012) 1.25
Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size. Radiat Oncol (2010) 1.08
Radical irradiation of extracranial oligometastases. J Clin Oncol (2014) 1.07
Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours. Br J Radiol (2012) 0.96
Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). Radiat Oncol (2013) 0.95
Stereotactic body radiotherapy for pulmonary metastases. Prognostic factors and adverse respiratory events. Strahlenther Onkol (2013) 0.94
Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience. J Radiat Res (2012) 0.92
Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis. Cancer Res Treat (2013) 0.92
Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases. Pulm Med (2012) 0.91
Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol (2014) 0.90
Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence. Pulm Med (2012) 0.90
Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry. Radiat Oncol (2015) 0.89
Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer. World J Gastroenterol (2014) 0.87
Analysis of biologically equivalent dose of stereotactic body radiotherapy for primary and metastatic lung tumors. Cancer Res Treat (2014) 0.87
Radiation pneumonitis after stereotactic radiation therapy for lung cancer. World J Radiol (2014) 0.84
Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation. Front Oncol (2016) 0.83
Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy. J Radiat Res (2012) 0.82
Oligometastases: the new paradigm and options for radiotherapy. A critical review. Strahlenther Onkol (2013) 0.82
Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis (2014) 0.82
Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol (2014) 0.82
Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions. J Radiat Res (2016) 0.81
Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases. Radiat Oncol (2014) 0.81
Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases. Jpn J Clin Oncol (2016) 0.80
SBRT for lung oligometastases: Who is the perfect candidate? Rep Pract Oncol Radiother (2014) 0.80
Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours. Cancer Imaging (2012) 0.80
Carbon ion radiotherapy for oligo-recurrent lung metastases from colorectal cancer: a feasibility study. Radiat Oncol (2014) 0.79
Oligometastasis and oligo-recurrence: more than a mirage. Radiat Oncol (2014) 0.79
Prognostic impact of average iodine density assessed by dual-energy spectral imaging for predicting lung tumor recurrence after stereotactic body radiotherapy. J Radiat Res (2016) 0.79
Cancer of the pelvis: definitive three-dimensional conformal radiotherapy for patients with isolated recurrence in the para-aortic lymph nodes. J Radiat Res (2012) 0.79
Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume. J Radiat Res (2014) 0.79
Stereotactic body radiotherapy: current strategies and future development. J Thorac Dis (2016) 0.78
Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study. J Radiat Res (2015) 0.78
Carbon ion radiotherapy for oligo-recurrence in the lung. Pulm Med (2013) 0.78
Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: A meta-analysis. Thorac Cancer (2016) 0.75
Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer. Radiat Oncol (2015) 0.75
Oligometastatic disease, the curative challenge in radiation oncology. World J Clin Oncol (2015) 0.75
Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses. Case Rep Oncol (2010) 0.75
Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy. Radiat Oncol (2012) 0.75
Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry's experience. Radiat Oncol (2017) 0.75
Stereotactic body radiation therapy for post-pulmonary lobectomy isolated lung metastasis of thoracic tumor: survival and side effects. BMC Cancer (2014) 0.75
The use of isodose levels to interpret radiation induced lung injury: a quantitative analysis of computed tomography changes. Quant Imaging Med Surg (2016) 0.75
Particle beam radiation therapy using carbon ions and protons for oligometastatic lung tumors. Radiat Oncol (2014) 0.75
Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer. Visc Med (2017) 0.75
Oligometastases of Gastrointestinal Cancer Origin. Visc Med (2017) 0.75
Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer (2004) 4.54
Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys (2005) 4.14
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol (2007) 3.91
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys (2010) 3.66
Thyroid gland tumor diagnosis at US elastography. Radiology (2005) 3.26
Cervical lymph node metastases: diagnosis at sonoelastography--initial experience. Radiology (2007) 2.56
Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency. Int J Radiat Oncol Biol Phys (2005) 2.19
Treatment outcome of medium-dose-rate intracavitary brachytherapy for carcinoma of the uterine cervix: comparison with low-dose-rate intracavitary brachytherapy. Int J Radiat Oncol Biol Phys (2012) 2.00
Surgical results of anomalous origin of the right pulmonary artery from the ascending aorta including reoperation for infrequent complications. Ann Thorac Surg (2008) 1.90
A linkage map for brown trout (Salmo trutta): chromosome homeologies and comparative genome organization with other salmonid fish. Genetics (2006) 1.89
Comparative genome analysis of the primary sex-determining locus in salmonid fishes. Genome Res (2003) 1.85
Vertebrate POLQ and POLbeta cooperate in base excision repair of oxidative DNA damage. Mol Cell (2006) 1.79
Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res (2007) 1.77
A Y-linked anti-Müllerian hormone duplication takes over a critical role in sex determination. Proc Natl Acad Sci U S A (2012) 1.74
Long-term effectiveness of total arch replacement for type A aortic dissection. Ann Thorac Surg (2005) 1.54
Characteristics of patients who developed radiation pneumonitis requiring steroid therapy after stereotactic irradiation for lung tumors. Cancer J (2006) 1.52
Current concepts in age-related hearing loss: epidemiology and mechanistic pathways. Hear Res (2013) 1.51
Tumor hypoxia: a target for selective cancer therapy. Cancer Sci (2003) 1.49
Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys (2002) 1.48
Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys (2009) 1.47
Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med (2011) 1.45
Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys (2012) 1.43
Effects of antioxidants and NO on TNF-alpha-induced adhesion molecule expression in human pulmonary microvascular endothelial cells. Respir Med (2004) 1.41
Long-term effect of repeated lidocaine injections into the external oblique for upper camptocormia in Parkinson's disease. Parkinsonism Relat Disord (2012) 1.41
APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep (2012) 1.40
A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol (2010) 1.39
Persistent left superior vena cava into left atrium. Lancet (2006) 1.39
The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem (2008) 1.38
Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging (2005) 1.35
Salvage lung resection for non-small cell lung cancer after stereotactic body radiotherapy in initially operable patients. J Thorac Oncol (2010) 1.35
Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun (2012) 1.30
Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol (2007) 1.29
Development of a four-dimensional image-guided radiotherapy system with a gimbaled X-ray head. Int J Radiat Oncol Biol Phys (2006) 1.29
Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 1.27
Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res (2002) 1.27
The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun (2007) 1.22
Identification and characterization of a novel human collectin CL-K1. Microbiol Immunol (2006) 1.20
Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology (2003) 1.20
Self-assembling nanoprobes that display off/on 19F nuclear magnetic resonance signals for protein detection and imaging. Nat Chem (2009) 1.16
Permanent Genetic Resources added to Molecular Ecology Resources Database 1 May 2009-31 July 2009. Mol Ecol Resour (2009) 1.15
Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest (2015) 1.15
Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol (2003) 1.14
Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.14
Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res (2009) 1.13
Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol (2010) 1.12
Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke (2010) 1.11
Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. Int J Clin Oncol (2007) 1.11
Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med (2006) 1.10
Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure. J Neurooncol (2002) 1.10
Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403). Phys Med Biol (2006) 1.10
General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer (2005) 1.08
Cell growth inhibitory effect of cinnamic acid derivatives from propolis on human tumor cell lines. Biol Pharm Bull (2003) 1.07
Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus. Virology (2004) 1.07
Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys (2011) 1.07
Microenvironment and radiation therapy. Biomed Res Int (2012) 1.06
M(2) and M(3) muscarinic receptor-mediated contractions in longitudinal smooth muscle of the ileum studied with receptor knockout mice. Br J Pharmacol (2005) 1.05
TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci (2008) 1.04
Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element. Acta Oncol (2006) 1.04
The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv Drug Deliv Rev (2009) 1.03